GlobeNewswire by notified

Subsea 7 S.A. notification of major holding

Share

Luxembourg –3 May 2024 – Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced that, on 3 May 2024, Barclays Capital Securities Limited1 informed the Company that it had breached thresholds provided for by Luxembourg’s Transparency Law of 11 January 2008 on transparency requirements for issuers of securities as amended (the “Transparency Law”) as follows:

  • On 30 April 2024 the total number of voting rights in the Company according to Article 8 and 9 of the Transparency Law attached to shares was 1,044,272
  • On 30 April 2024 the total number of voting rights in the Company attached to financial instruments with similar economic effect according to Article 12 (1) (a) of the Transparency Law (right to recall) was 13,906,019
  • On 30 April 2024 the total number of voting rights in the Company attached to financial instruments with similar economic effect according to Article 12 (1) (b) of the Transparency Law (swaps) was 499,740
  • When combined, the above positions equate to 5.07% of voting rights of Subsea 7 S.A.

A copy of the notifications received from Barclays is available on the Subsea7 website www.subsea7.com.

1 A wholly-owned subsidiary of Barclays Plc

*******************************************************************************
Subsea7 is a global leader in the delivery of offshore projects and services for the evolving energy industry, creating sustainable value by being the industry’s partner and employer of choice in delivering the efficient offshore solutions the world needs.

Subsea7 is listed on the Oslo Børs (SUBC), ISIN LU0075646355, LEI 222100AIF0CBCY80AH62.

*******************************************************************************

Contact for investment community enquiries:
Katherine Tonks
Investor Relations Director
Tel +44 20 8210 5568
ir@subsea7.com

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

This stock exchange release was published by Katherine Tonks, Investor Relations, Subsea7, on 3 May 18:30 CET

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Weekly share repurchase program transaction details29.5.2024 18:33:44 CEST | Press release

May 29, 2024 SBM Offshore reports the transaction details related to its EUR65 million (c. US$70 million) share repurchase program for the period May 23, 2024 through May 29, 2024. The repurchases were made under the EUR65 million share repurchase program announced on February 29, 2024 and effective from March 1, 2024. The objective of the program is to reduce share capital. Information regarding the progress of the share repurchase program and the aggregate of the transactions (calculated on a daily basis) for the period March 1, 2024 through May 29, 2024 can be found in the top half of the table below. Further detailed information regarding both the progress of the share repurchase program and all individual transactions can be accessed via the Investors section of the Company’s website. Share Repurchase ProgramOverall progress Share Repurchase Program:Total Repurchase AmountEUR 65,000,000Cumulative Repurchase AmountEUR 21,944,332Cumulative Quantity Repurchased1,553,031Cumulative Ave

Progress on cosmetics plant project: completion of the basic engineering phase and success of the related test campaign29.5.2024 17:45:00 CEST | Press release

PRESS RELEASE Progress on cosmetics plant project: completion of the basic engineering phase and success of the related test campaign Evry, 29 May 2024 – 05:45 p.m.: Global Bioenergies has successfully completed the basic engineering phase of its plant project dedicated to the cosmetics markets whose commissioning is scheduled for mid-2027. The engineering work carried out as part of the basic engineering has precisely defined the each of the units that will enable the fully integrated production of cosmetic-grade isobutene derivatives. It also confirms the project schedule and the nominal CAPEX of 65 million euros (i.e. a maximum CAPEX of 80 million euros taking into account contingencies). Roland Desvignes, Industrial Director of Global Bioenergies, explains: “Two engineering firms have been mandated, the first to handle the biological side, and the second the part dedicated to green chemistry. Their respective expertise gives us a very good vision of the plant's blueprints. We are n

Vaisala Corporation: Share Repurchase 29.5.202429.5.2024 17:30:00 CEST | Press release

VAISALA CORPORATIONSTOCK EXCHANGE RELEASE 29.5.2024Vaisala Corporation: Share Repurchase 29.5.2024In the Helsinki Stock ExchangeTrade date 29.5.2024Bourse trade BuyShare VAIASAmount 500SharesAverage price/ share 39,9700EURTotal cost 19 985,00EURVaisala Corporation now holds a total of 138 828 sharesincluding the shares repurchased on 29.5.2024On behalf of Vaisala CorporationNordea Bank OyjJanne Sarvikivi Sami HuttunenAdditional information Paula Liimattatel +358 9 8949 2020, ir@vaisala.comwww.vaisala.com Vaisala is a global leader in measurement instruments and intelligence for climate action. We equip our customers with devices and data to improve resource efficiency, drive energy transition, and care for the safety and well-being of people and societies worldwide. With almost 90 years of innovation and expertise, we employ a team of over 2,300 experts committed to taking every measure for the planet. Vaisala series A shares are listed on the Nasdaq Helsinki stock exchange.vaisala.com

Thierry Amarger co-opted as independent Director by Vantiva29.5.2024 17:30:00 CEST | Press release

Press Release Thierry Amarger co-opted as independent Director by Vantiva Paris, France – May 29, 2024 – Vantiva (Euronext Paris: VANTI), announced that on the recommendation of the Governance and Social Responsibility Committee, Vantiva's Board of Directors, convened on May 28, 2024, to co-opt Thierry Amarger as an independent Director of Vantiva. He replaces Dominique D'Hinnin, who resigned on April 5, 2024. This co-option took effect immediately. Thierry Amarger's co-option will be submitted to shareholders for ratification at the Annual General Meeting to be held on June 19, 2024. His term of office will expire at the close of the Annual General Meeting for fiscal year 2024. Brian Shearer, Chairman of the Board of Directors, said: “I welcome Thierry Amarger to our Board of Directors. He is a proven leader within multiple areas of the global telecommunications ecosystem, and his skillset will be immediately beneficial to all Vantiva stakeholders.” Mr. Amarger, a French national, is

Zealand Pharma to participate in upcoming healthcare investor conferences in June 202429.5.2024 17:10:00 CEST | Press release

Press release – No. 5 / 2024 Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024 Copenhagen, Denmark, May 29, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that Adam Steensberg, President and CEO, will participate in fireside chats at the following healthcare investor conferences in June: Jefferies Global Healthcare Conference, June 4-6 in New York City Wednesday, June 5 at 10:00 a.m. ET (4:00 p.m. CET) A webcast of the fireside chat will be available at https://wsw.com/webcast/jeff302/register.aspx?conf=jeff302&page=zeal&url=https://wsw.com/webcast/jeff302/zeal/1839808 and accessible through the Events page in the Investor section of Zealand Pharma’s website at https://www.zealandpharma.com/events/ where a replay will also be archived after the fireside chat. Goldman Sachs 45th Annual Global Healthcare Conference, Jun

HiddenA line styled icon from Orion Icon Library.Eye